Hong Kong-based biopharmaceutical company Hutchison China Meditech intends to raise funds by issuing American Depository Shares in a public offering.

The proceeds are intended to be used for general corporate purposes.

EastGate Biotech and AC Nova Technologies have formed a joint venture (JV) to commercialise evidence-based natural therapies focused on glucose balance and cardiovascular health, enabling them to provide complementary therapies to slow down aging symptoms.

Both companies involved in the JV are based in Canada.

"Hong Kong-based biopharmaceutical company Hutchison China Meditech intends to raise funds by issuing American Depository Shares in a public offering."

US-based pharmaceutical company Tocagen has announced that it intends to raise between $72.5m and $87m through an initial public offering (IPO) of 7.25 million shares valued between $10 and $12 a share.

Underwriters will be granted a 30-day option to purchase up to an additional 1.08 million shares to cover any over-allotment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Naia Rare Diseases is set to raise funds for its clinical programme and to continue its first human trial in patients with short bowel movements through a series B financing round from Cedars-Sinai Medical Center.

Naia Rare Diseases is a biopharmaceutical company based in the US.